Spontaneous Bacterial Peritonitis, Ascites, Liver Cirrhosis
Conditions
Brief summary
The aim of the study is to compare the effectiveness of rifaximin versus norfloxacin for secondary prevention of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites.
Detailed description
This study will be carried out on 100 patients with liver cirrhosis and ascites who will be enrolled from Tanta University, Tropical Medicine Department in the period between January 2014 to 6 months. The selected patients will be randomly assigned to receive 400 mg of norfloxacin daily or 1200 mg of rifaximin daily and will be classified into two groups : Group 1 : 50 patients will be treated with 1200 mg of rifaximin daily. Group 2 : 50 patients will be treated with 400 mg of norfloxacin daily.
Interventions
DRUGRifaximin
rifaximin 1200 mg daily versus norfloxacin 400 mg once daily
DRUGNorfloxacin
FDA approved:400mg once daily
Sponsors
Tanta University
Sherief Abd-Elsalam
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Previous episode of SBP * Total protein in the ascitic fluid below or equal to 1.5 g/dL
Exclusion criteria
* Allergy to quinolones * Antibiotic therapy in the 2 weeks preceding inclusion * Recent ( within the previous 2 weeks) episode of digestive hemorrhage * Hepatocellular carcinoma or other neoplasias able to shorten life expectancy * Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with recurrence of SBP | 6 months | The total number of paper of participitants with recurrence of SBP |
Countries
Egypt
Contacts
Primary ContactSherief M. Abd-Elsalam, Lecturer
Outcome results
None listed